Current Issue

Sponsored
Keywords

Companion Diagnostics - Related Content

BioPerspectives: Personalized Medicine: From Biomarkers to Companion Diagnostics
This third chapter of a five-part series talks about coordinating diagnostic test kit development between pharmaceutical companies and diagnostic manufacturers.
Corporate Profiles: Exploiting Folate Pathways to Treat Cancer
Endocyte Uses an Imaging Agent to Select Patients Likely to Respond to Its Therapies
BioMarket Trends: Rise of Cell-Based Immunotherapy
Wall Street BioBeat: Companion Dx and Personalized Medicine
Feature Articles: FDASIA’s Impact on Novel IVDs
Though Not Revolutionary, New Act Could Offer Significant Benefits to In Vitro Diagnostic Firms

Companion Diagnostics: 52 Pick-Up
May 13, 2013
Check out our three lists of 52 CDx: those approved by the FDA, those under review right now, and those that may be coming soon.
This Time Last Year: Diagnostic Deals, mAb Therapeutics, and Obesity Drug Development
June 1, 2012
Among big news was Roche’s companion diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA’s Avastin decision.
Standardization Key to Taking Next-Generation Sequencing to the Next Level
January 27, 2012
As NGS technology makes steady progress with faster and cheaper machines, regulation will have to keep up.
Companies with Cancer Therapeutic Candidates Ramp Up Companion Diagnostic Efforts
July 25, 2011
As regulatory framework gets fine-tuned, firms realize the importance of having a biomarker strategy.
Concurrent Dx/Rx Review Will Require More Collaboration at FDA and More Outreach by Industry
July 22, 2011
Agency issued draft guidance on companion diagnostic approval on July 14.